Seasonal and pandemic influenza viruses continue to be a leading global health concern.
Emerging resistance to the current drugs and the variable efficacy of vaccines underscore …

Influenza is a global human health threat, and there is an immediate need for new antiviral
therapies to circumvent the limitations of vaccination and current small molecule therapies …

The influenza virus is responsible for millions of cases of severe illness annually. Yearly
variance in the effectiveness of vaccination, coupled with emerging drug resistance …

Influenza is a serious hazard to human health that causes hundreds of thousands of deaths
annually. Though vaccines and current therapeutics can blunt some of the perilous impact of …

It is generally recognised that novel antiviral drugs, less prone to resistance, would be a
desirable alternative to current drug options in order to be able to treat potentially serious …

Inhibition of the endonuclease activity of influenza RNA-dependent RNA polymerase is
recognized as an attractive target for the development of new agents for the treatment of …

Significant efforts have been reported on the development of influenza antivirals including
inhibitors of the RNA-dependent RNA polymerase PA N-terminal (PAN) endonuclease …

Emerging influenza viruses are a serious threat to human health because of their pandemic
potential. A promising target for the development of novel anti-influenza therapeutics is the …

Influenza virus (IFV) causes periodic global influenza pandemics, resulting in substantial
socioeconomic loss and burden on medical facilities. Yearly variation in the effectiveness of …

The propensity of influenza virus to develop resistance to commonly prescribed drugs
highlights the need for continuing development of new therapeutics. Biological and …